BACKGROUND: The appropriate duration of dual-antiplatelet therapy (DAPT) after drug-eluting stent (DES) placement remains controversial. PURPOSE: To summarize data on clinical outcomes with longer- versus shorter-duration DAPT after DES placement in adults with coronary artery disease. DATA SOURCES: Ovid MEDLINE and EMBASE, 1996 to 27 March 2015, and manual screening of references. STUDY SELECTION: Randomized, controlled trials comparing longer- versus shorter-duration DAPT after DES placement. DATA EXTRACTION: Two reviewers screened potentially eligible articles; extracted data on populations, interventions, and outcomes; assessed risk of bias; and used the Grading of Recommendations Assessment, Development and Evaluation guidelines to rate overall confidence in effect estimates. DATA SYNTHESIS: Among 1010 articles identified, 9 trials including 29,531 patients were eligible; data were complete for 28,808 patients. Moderate-quality evidence showed that longer-duration DAPT decreased risk for myocardial infarction (risk ratio [RR], 0.73 [95% CI, 0.58 to 0.92]) and increased mortality (RR, 1.19 [CI, 1.04 to 1.36]). High-quality evidence showed that DAPT increased risk for major bleeding (RR, 1.63 [CI, 1.34 to 1.99]). LIMITATION: Confidence in estimates were decreased owing to imprecision for most outcomes (particularly myocardial infarction), risk of bias from limited blinding in 7 of 9 studies, indirectness due to variability in use of first- and second-generation stents, and off-protocol use of DAPT in some studies. CONCLUSION: Extended DAPT is associated with approximately 8 fewer myocardial infarctions per 1000 treated patients per year but 6 more major bleeding events than shorter-duration DAPT. Because absolute effects are very small and closely balanced, decisions regarding the duration of DAPT therapy must take into account patients' values and preference. PRIMARY FUNDING SOURCE: None.
BACKGROUND: The appropriate duration of dual-antiplatelet therapy (DAPT) after drug-eluting stent (DES) placement remains controversial. PURPOSE: To summarize data on clinical outcomes with longer- versus shorter-duration DAPT after DES placement in adults with coronary artery disease. DATA SOURCES: Ovid MEDLINE and EMBASE, 1996 to 27 March 2015, and manual screening of references. STUDY SELECTION: Randomized, controlled trials comparing longer- versus shorter-duration DAPT after DES placement. DATA EXTRACTION: Two reviewers screened potentially eligible articles; extracted data on populations, interventions, and outcomes; assessed risk of bias; and used the Grading of Recommendations Assessment, Development and Evaluation guidelines to rate overall confidence in effect estimates. DATA SYNTHESIS: Among 1010 articles identified, 9 trials including 29,531 patients were eligible; data were complete for 28,808 patients. Moderate-quality evidence showed that longer-duration DAPT decreased risk for myocardial infarction (risk ratio [RR], 0.73 [95% CI, 0.58 to 0.92]) and increased mortality (RR, 1.19 [CI, 1.04 to 1.36]). High-quality evidence showed that DAPT increased risk for major bleeding (RR, 1.63 [CI, 1.34 to 1.99]). LIMITATION: Confidence in estimates were decreased owing to imprecision for most outcomes (particularly myocardial infarction), risk of bias from limited blinding in 7 of 9 studies, indirectness due to variability in use of first- and second-generation stents, and off-protocol use of DAPT in some studies. CONCLUSION: Extended DAPT is associated with approximately 8 fewer myocardial infarctions per 1000 treated patients per year but 6 more major bleeding events than shorter-duration DAPT. Because absolute effects are very small and closely balanced, decisions regarding the duration of DAPT therapy must take into account patients' values and preference. PRIMARY FUNDING SOURCE: None.
Authors: Monica Hultcrantz; David Rind; Elie A Akl; Shaun Treweek; Reem A Mustafa; Alfonso Iorio; Brian S Alper; Joerg J Meerpohl; M Hassan Murad; Mohammed T Ansari; Srinivasa Vittal Katikireddi; Pernilla Östlund; Sofia Tranæus; Robin Christensen; Gerald Gartlehner; Jan Brozek; Ariel Izcovich; Holger Schünemann; Gordon Guyatt Journal: J Clin Epidemiol Date: 2017-05-18 Impact factor: 6.437
Authors: Mohammed Qintar; Adnan K Chhatriwalla; Suzanne V Arnold; Fengming Tang; Donna M Buchanan; Ali Shafiq; Yashashwi Pokharel; Dave deBronkart; Javed M Ashraf; John A Spertus Journal: Catheter Cardiovasc Interv Date: 2017-02-07 Impact factor: 2.692
Authors: Pedro A Villablanca; Daniele Massera; Verghese Mathew; Sripal Bangalore; Panagiota Christia; Irving Perez; Ningxin Wan; Stefanie Schulz-Schüpke; David F Briceno; Anna E Bortnick; Mario J Garcia; Richard Lucariello; Mark Menegus; Robert Pyo; Jose Wiley; Harish Ramakrishna Journal: Medicine (Baltimore) Date: 2016-12 Impact factor: 1.889
Authors: Raphaela Lohaus; Jonathan Michel; Katharina Mayer; Anna Lena Lahmann; Robert A Byrne; Annabelle Wolk; Jurrien M Ten Berg; Franz-Josef Neumann; Yaling Han; Tom Adriaenssens; Ralph Tölg; Melchior Seyfarth; Michael Maeng; Bernhard Zrenner; Claudius Jacobshagen; Jochen Wöhrle; Sebastian Kufner; Tanja Morath; Tareq Ibrahim; Isabell Bernlochner; Marcus Fischer; Heribert Schunkert; Karl-Ludwig Laugwitz; Julinda Mehilli; Adnan Kastrati; Stefanie Schulz-Schüpke Journal: Sci Rep Date: 2016-09-14 Impact factor: 4.379